Every 10-Q that AEON Biopharma, Inc. (AEON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AEON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEON filings page.
AEON Biopharma, Inc. reported continued operating losses while advancing ABP-450 as a proposed biosimilar to BOTOX. For the six months ended June 30, 2026, the company recorded a net loss of $12.9 million and had an accumulated deficit of $483.8 million. Cash and cash equivalents were $3.4 million and total assets $5.9 million, against total liabilities of $21.3 million, resulting in a stockholders’ deficit of $15.4 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative operating cash flow and limited cash. AEON is funding operations through equity and structured financings, including an at-the-market program (2.3 million shares for $2.6 million in the first half of 2026), a $6.0 million PIPE, the exchange of $15.0 million of Daewoong convertible notes into equity, a new $1.5 million senior secured convertible note, and approximately $13.6 million of net proceeds from a July 2026 offering.
AEON progressed its ABP-450 biosimilar program, holding FDA biosimilar meetings, commencing analytical studies, and planning to complete most analytical comparability work in 2026. However, future development, regulatory approval and commercialization remain dependent on securing additional capital under uncertain market and financing conditions.
AEON Biopharma, Inc. reported a net loss of $11.8 million for the three months ended March 31 2026, compared with net income of $9.1 million a year earlier. Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development expenses were $2.0 million.
Results were heavily influenced by fair value movements on financing instruments, including an $8.7 million loss on convertible notes and a $4.7 million gain on warrants. AEON ended the quarter with cash and cash equivalents of $6.2 million and total liabilities of $25.4 million, resulting in a stockholders’ deficit of $16.8 million.
The company raised equity through its at-the-market program, issuing 1,278,776 shares for net proceeds of about $1.7 million, and completed a $6.0 million PIPE financing spanning late 2025 and early 2026. It also exchanged $15.0 million of Daewoong-held convertible notes into equity, a new $1.5 million note and 8.0 million warrants at $1.09392/share.
Management disclosed recurring losses, a significant accumulated deficit of $482.6 million, limited cash and dependence on additional financing, concluding there is substantial doubt about AEON’s ability to continue as a going concern. The company continues developing its ABP‑450 botulinum toxin biosimilar program and plans to advance analytical and regulatory interactions with the FDA during 2026.
AEON Biopharma filed its Q3 2025 10‑Q, reporting continued operating losses and tight liquidity. The company posted a net loss of $4.5 million for the three months ended September 30, 2025, compared with a net loss of $6.2 million a year ago. Operating expenses declined as selling, general and administrative fell to $1.9 million and research and development to $0.6 million.
Cash and cash equivalents were $5.9 million at September 30, 2025, up from $13 thousand at December 31, 2024, aided by a January 2025 public offering that generated net proceeds of $18.3 million and modest ATM issuances. The company disclosed “substantial doubt” about its ability to continue as a going concern.
AEON executed a 1‑for‑72 reverse stock split on February 24, 2025 and had 11,643,786 shares outstanding at September 30, 2025. In the offering, Series A and Series B warrants were issued with the exercise price reset to $8.06; 3,438,095 Series B warrants were cashlessly exercised, issuing 10,314,285 shares. Convertible notes with Daewoong totaled $15.0 million principal (fair value $17.1 million as of September 30, 2025, interest 15.79%). AEON is pursuing a Botox biosimilar pathway and held a BPD Type 2a FDA meeting on November 19, 2025.
AEON Biopharma reported a period of transition as it pivots ABP-450 development toward a biosimilar pathway after discontinuing Phase 2 migraine trials in May 2024. The company completed a 1-for-72 reverse stock split and raised net proceeds of approximately $18.3 million from a January 2025 public offering and has an ATM program with about $49.8 million remaining. As of June 30, 2025, AEON held $8.4 million in cash and total assets of $11.7 million, against total liabilities of $27.5 million, resulting in a stockholders' deficit of $15.9 million. The company recorded a $75.6 million non‑cash loss on warrant issuance and recognized fair value movements on convertible notes and contingent consideration that materially affected reported (loss) income. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing will be required to advance analytical studies, a planned FDA BPD Type 2a meeting and further development of ABP-450.